Alzheimer's Research UK’s Post

Here's a sobering fact: Alzheimer's and other forms of dementia currently affect more than 50 million people worldwide, and this number is expected to triple by 2050.💡 June is Alzheimer's & Brain Awareness Month, an opportune time to discuss, raise awareness, and inform about preventive measures for this brain-degrading disease. In my own experience, having worked closely with the elderly population, I've seen first-hand the impact this illness can have not just on patients, but on their families as well. Early detection and research are crucial to mitigating its devastating effects. That's why I appreciate how companies like Google are leveraging their technological prowess in the fight against Alzheimer's.🧠 Using AI to analyze MRI scans and knowingly using voice-tech to detect speech pattern alterations might just be our hope for early disease detection. They didn't stop there; In collaboration with Alzheimer's Association, Google created a virtual reality experience that simulates the life of an Alzheimer's patient. 👁️🗨️ An innovative approach to empathy-building! In honor of Alzheimer's & Brain Awareness Month, what steps are you taking to boost your brain health and promote cognitive longevity? They say prevention is better than cure; let's keep that in mind

For patients suffering from Alzheimer’s disease, no memories are safe — from the recollections of daily responsibilities to our most cherished moments. And despite having invested billions of dollars over the last 30 years into Alzheimer’s research, the pharmaceutical industry has approved few drugs, all of which are very expensive, and only slow the rate of decline. However, some Alzheimer’s patients, refusing to accept this prognosis, are turning to a new method, spearheaded by American neurologist Dr Dale Bredesen. This precision medicine approach uses the expanded health data of each patient to find the root cause of their illness, and generate personalized protocols. Yet Dr. Bredesen, best-selling author of The End of Alzheimer’s, faces constant skepticism from the mainstream medical community for his method, and his research was repeatedly denied approval for clinical trials until 2019. Even so, many patients following the protocol show signs of reversing their cognitive decline. Narrated by Michael Bublé, Memories for Life – Reversing Alzheimer’s shows the eye-opening results of this life-changing treatment and questions why something with the potential to reverse such a devastating disease is not being embraced by medical researchers. What if this is the best chance we have to hold on to the most precious of things – our memories? Go to MemoriesForLifeFilm.com and watch the best film on fighting dementia. We all need to start making lifestyle changes. To save your memories, you must start saving your memory. https://lnkd.in/g4HE2ME2

#WorldAlzMonth 📅 World Alzheimer's Day, held annually on September 21st, is a key part of Alzheimer's Month. This global initiative aims to dispel misconceptions about dementia and Alzheimer's disease, while offering support and encouragement to families affected by these conditions. Well-developed prediction algorithms for Alzheimer's Disease (AD) could revolutionize early intervention. By identifying individuals at risk, these algorithms could enable timely interventions to slow the progression of this debilitating disease. AD is characterized by a gradual decline in memory, cognitive function, and behavior. While it primarily affects individuals over 65, it's important to note that younger individuals can also be affected. Although various therapies exist to manage symptoms, a definitive cure for AD remains elusive. 📊 Research suggests that abnormal protein accumulation in and around brain cells plays a significant role in AD development. A recent study highlights the potential of radiomic models based on positron emission tomography (PET) images to predict the progression of AD from mild cognitive impairment. This groundbreaking research could pave the way for more accurate and effective early diagnosis and treatment. Read our blog post: https://lnkd.in/d77bNA2A #TimetoActOnDementia #TimeToActOnAlzheimers

It's great to witness the evolution of blood testing being applied to dementia research. This groundbreaking trial, spearheaded by @University College London and the University of Oxford, marks a significant step forward in the fight against Alzheimer's and other forms of dementia. This initiative underscores the importance of innovative approaches in healthcare and holds promise for improving outcomes for individuals and families affected by dementia. As a remote blood testing company, we're excited to witness advancements in diagnostic capabilities and are optimistic about the positive impact these blood tests could have on early detection and treatment options for dementia patients. Congratulations to all involved in the Blood Biomarker Challenge, including Alzheimer's Society, Alzheimer's Research UK, The National Institute for Health and Care Research, Gates Ventures, and the generous contribution of £5m from People's Postcode Lottery. See the article here: https://lnkd.in/enkn32re #DementiaResearch #BloodTestingInnovation #HealthcareAdvancements #diagnostics #diagnostictesting #diagnosticsasaservice #bloodtest #bloodtesting #homebloodtest #remotebloodtesting

The Alzheimer's Association®'s International Conference (#AAIC24) is the largest international meeting dedicated to dementia research and clinical care. This year over 7,000 people attended AAIC from 93 countries! Here's what Abigail O'Connell, Synapticure's Director of Clinical Trial Operations, shared about her time at AAIC: "I always leave AAIC inspired by the latest in dementia science and care. It's an incredible opportunity to connect with others in the field and learn from the work being done in dementia worldwide. This year's highlights included advances in disease-modifying treatments, new treatment approaches, and expanding research on blood-based biomarkers. These developments align with the launch of CMS' #GUIDE program, promising comprehensive care for those previously unable to access multidisciplinary care and support." Learn more about Synapticure's dementia care program and GUIDE at synapticure.com

🧠 Exciting developments in Alzheimer's research! A new approach offers hope for regaining lost memories in Alzheimer's patients. Check out this article to learn about the innovative research paving the way for potential memory restoration. It's inspiring to see strides being made in the fight against Alzheimer's disease. Let's spread awareness and support the journey towards finding effective treatments. Read now: https://lnkd.in/eYNSgUCk #Alzheimers #MemoryRestoration #MedicalResearch #HealthcareInnovation #SpreadAwareness 🌟💡

These two drugs are a huge step in the right direction, but a clear example of how much more needs to be done. Repurposing drugs, and developing cheaper and more accessible diagnostics are just two examples of this. Hear what Dr Maura Malpetti has to say on the BBC Panorama on Alzheimer's which aired last night. #dementiaresearch

The GUIDE Model by CMS 🧠💙 is an innovative approach enhances care for dementia patients and supports caregivers with: 1. Comprehensive care coordination 2. Personalized care plans 3. Resources & education for caregivers 4. Better access to medical & community services 5. Continuous quality improvement Do you know a family enrolled in Medicare Part A and B (not Medicare Advantage) that could benefit from these services? Learn more about Synapticure Inc. part in the GUIDE Model and schedule an appointment. Check out our website for more information or email support@synapticure.com Together, we can improve the dementia care experience! #DementiaCare #HealthcareInnovation #CMSGuideModel

Groundbreaking research has identified four proteins, GFAP, NEFL, GDF15, and LTBP2, that can predict the onset of dementia more than a decade before diagnosis. This discovery brings us a step closer to a simple blood test for early detection of dementia. Individuals with higher GFAP levels were found to be 2.32 times more likely to develop dementia. The findings strongly highlight GFAP as an optimal biomarker for dementia prediction. This could revolutionize how we screen people at high risk for dementia and enable early intervention. You can find the research on Nature Aging via the following link: https://lnkd.in/eTKka5-b